Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)
Notice Number:

Key Dates

Release Date:

February 4, 2021

First Available Due Date:
June 05, 2021
Expiration Date:
New Date December 1, 2022 (Original Date: January 08, 2023) per issuance of NOT-AI-23-003

Related Announcements

NOT-AI-23-003 - Notice of Early Expiration of "Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)", NOT-AI-21-008

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)



The complement system is an evolutionarily conserved component of innate immunity that serves as a first line of defense against infection by lysing infected cells and opsonizing pathogens for their removal by phagocytes. There are three major pathways of complement activation that are triggered independently, including the classical, the lectin, and the alternative pathways, all of which merge at the step of C3 activation. These pathways function as cascades of proteases that activate each other in an enzymatic fashion to lyse infected cells.

Although most complement is produced by the liver to act systemically, complement may act locally within cells or in tissues. Complement components also are produced in a broad range of immune and other cell types, such as endothelial cells. In addition to functioning in the above-mentioned enzymatic cascades, individual complement components have been shown to play other critical roles in immune responses. Examples of non-canonical roles of complement include: C3 can serve as a damage-associated molecular pattern (DAMP) that enhances intracellular innate immunity and also acts as a controller of T lymphocyte survival; autocrine activation of complement regulator CD46 plays a key role in nutrient uptake and enhances cellular metabolism essential for Th1 responses; intracellular C5 activation was reported to be essential for NLRP3 inflammasome assembly in CD4+T cells; signaling through C5aR1 located on mitochondria is involved in the development of reactive oxygen species (ROS); C1q has been reported to enhance phagocytosis and efferocytosis in human monocytes and suppress inflammatory responses; C1qR is reported to be located in mitochondria where it is involved in mitochondrial biogenesis, can influence mitochondrial metabolism of CD8 T cells, and plays a pivotal role in regulating effector CD8 T cell responses in autoimmunity and viral infection. There are additional reports of interaction between individual complement components and innate signaling pathways, including Toll-Like Receptors.

While serving to protect against infection either directly or indirectly by influencing innate and adaptive immunity, dysregulation of complement can have deleterious effects. Pathogens induce local and systemic complement activation and inflammatory responses early during infection, which typically resolve. However, over activation or dysregulation of the complement cascade can cause collateral damage of cells and tissues, as illustrated by severe COVID-19 disease where over activation of the complement system appears to induce endothelial cell injury and death, leading to initiation of clotting cascades. These complications can lead to life-threatening illness and multi-organ failure.

The mechanisms by which complement components, receptors and pathways contribute to protective immune responses or pathogenesis remain to be fully elucidated. A better understanding of complement mechanism of action is critical for harnessing its positive effects in the development of adjuvants and vaccines, and for targeting it with therapeutics to reign in dysregulated complement responses.

Research Objectives

NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious diseases, including fundamental immunology research that aims to understand the complex interactions between pathogens and their human hosts and generate the knowledge essential for developing safe and effective treatments and vaccines. The mechanisms by which complement influences immune responses have been under appreciated, and a better understanding of complement action will inform high priority adjuvant and vaccine development, and also shed light on the pathogenesis of infections such as SARS CoV-2.

The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.

The work to be encouraged includes studies of the roles of complement components (molecules and/or receptors) during immune responses. Research areas of interest include, but are not limited to:

  • Studies of the role of complement during adaptive or innate immune cell activation, differentiation, function, homeostasis, and memory;
  • Mechanisms regulating the crosstalk of complement with other innate receptor systems;
  • The potential of targeting complement components in adjuvant development;
  • The role of complement components in immune pathogenesis of infection; and/or
  • Development of animal models or cell- or tissue-specific in vitro and in vivo systems for studying the roles of complement in regulating immune responses.

Application and Submission Information

This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through January 7, 2023.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

All instructions in theSF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include NOT-AI-21-008 in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.


Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Scientific/Research Contact(s)
Ari Joffe, Ph.D
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-761-7459

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices